.jpg)
Overview
SEQENS is a worldwide leader in developing and
producing active ingredients, pharmaceutical intermediates, specialty
ingredients, and cosmetics & personal care, leveraging 16 manufacturing
sites, 9 R&D centers, and 3,300 employees in 9 countries. As an integrated
player across the value chain – from raw materials to active ingredients and
from research and development to industrialization – SEQENS offers a broad
portfolio of active ingredients, pharmaceutical intermediates, and specialty
ingredients, develops, and industrializes the most demanding molecules, and
relies on its ability to innovate, develop, and implement the best available
technologies. Driven not only by a culture of excellence and
a strong entrepreneurial spirit but also strong values such as unity, agility,
and reactivity, our employees are committed to providing the highest level of
service and quality to more than 1500 customers around the world while acting
ethically in accordance with our strong Environmental, Social, and Governance
program.
Located in Devens (MA) for 20 years, SEQENS
Boston’Lab has acquired a strong expertise in developing custom New Chemical
Entities for pharmaceutical purposes. It combines the responsiveness of a small
company with the capacity and capabilities of a much larger one. Our
2023-inaugurated Innovation Center includes R&D labs and GMP suites for
non-GMP and GMP manufacturing, from grams to kilograms.
Company News
Seqens Group Opens Flagship Pharmaceutical R&D Center in Greater Boston
Feb 09, 2023
Posted by SEQENS CDMO NA
SEQENS Makes Multi-Million-Dollar Investment in U.S. R&D Laboratory (Devens, MA)
Mar 31, 2022
Posted by SEQENS CDMO NA